GlassScriptPhysician profile
Cassie Davis
NPI 1548616295
$3,990.37
in general payments reported to CMS, 2019-2025
37 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $33.40 · 2023: $572 · 2024: $1,461 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,669 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,668.61 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $568.92 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $389.32 | 2024-2025 | Unithroid |
| Lundbeck LLC | $321.98 | 2024-2025 | Rexulti, Vyepti |
| Axsome Therapeutics, INC. | $310.73 | 2024-2025 | Auvelity, Symbravo |
| Otsuka America Pharmaceutical, INC. | $294.04 | 2023-2025 | Rexulti |
| Ibsa Pharma INC. | $250.01 | 2021-2025 | Licart, Tirosint, Tirosint |
| Lilly USA, LLC | $218.06 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $164.96 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.67 | 2022-2025 | Trintellix |
| Astellas Pharma US INC | $150.58 | 2023-2025 | Veozah |
| Novo Nordisk INC | $116.21 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Azurity Pharmaceuticals, INC. | $114.74 | 2024-2025 | Azmiro, Horizant, Edarbyclor |
| Glaxosmithkline, LLC. | $77.84 | 2024 | Arexvy, Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $74.49 | 2021-2024 | Nexletol, Contrave, Onzetra Xsail |
| Noven Therapeutics, LLC | $66.53 | 2024-2025 | Xelstrym |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $65.42 | 2023-2024 | Korlym |
| Mayne Pharma Commercial LLC | $61.60 | 2023-2024 | |
| Exact Sciences Corporation | $57.92 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.38 | 2025 | Caplyta |
| Ironwood Pharmaceuticals, INC | $55.13 | 2023-2024 | Linzess |
| Bausch Health US, LLC | $54.05 | 2024 | Aplenzin |
| Collegium Pharmaceutical, INC. | $52.50 | 2021-2025 | Jornay Pm |
| Acella Pharmaceuticals, LLC | $36.59 | 2023-2024 | NP Thyroid 60 |
| Ani Pharmaceuticals, INC. | $30.62 | 2025 | Purified Cortrophin Gel |
| Intra-Sana Laboratories | $29.55 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Sumitomo Pharma America, INC. | $25.26 | 2025 | Gemtesa |
| Neos Therapeutics, LP | $20.91 | 2024 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $20.60 | 2024 | Austedo Xr |
| Xeris Pharmaceuticals, INC. | $19.66 | 2021 | |
| Amgen INC. | $18.81 | 2025 | Otezla, Repatha |
| Abbott Laboratories | $18.68 | 2024 | Freestyle Libre 3 |
| Antares Pharma, INC. | $15.97 | 2024 | Xyosted |
| Impel Pharmaceuticals INC. | $15.38 | 2023 | Trudhesa |
| Astrazeneca Pharmaceuticals LP | $14.05 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.72 | 2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.08 | 2021 | |
| Amarin Pharma, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassie Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.